• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 15-12G filed by Tyme Technologies Inc.

    9/30/22 4:05:54 PM ET
    $TYME
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TYME alert in real time by email
    15-12G 1 d378365d1512g.htm 15-12G 15-12G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 15

     

     

    CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

    UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

    OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)

    OF THE SECURITIES EXCHANGE ACT OF 1934.

    Commission File Number: 001-38169

     

     

    TYME TECHNOLOGIES, INC.

    (Exact name of registrant as specified in its charter)

     

     

    35 CambridgePark Drive, 4th Floor

    Cambridge, Massachusetts 02140

    (Address, including zip code, of Registrant’s Principal Executive Offices)

    Common Stock, par value $0.0001 per share

    (Title of each class of securities covered by this Form)

    N/A

    (Titles of all other classes of securities for which a duty to file reports under Section 13(a) or 15(d) remains)

     

     

    Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

     

    Rule 12g-4(a)(1)

       ☒  

    Rule 12g-4(a)(2)

       ☐  

    Rule 12h-3(b)(1)(i)

       ☒  

    Rule 12h-3(b)(1)(ii)

       ☐  

    Rule 15d-6

       ☐  

    Rule 15d-22(b)

       ☐  

    Approximate number of holders of record as of the certification or notice date: One*

     

    *

    On September 16, 2022, pursuant to an Agreement and Plan of Merger, by and among Syros Pharmaceuticals, Inc. (“Syros”), Tack Acquisition Corp. (“Merger Sub”) and Tyme Technologies, Inc. (“Tyme”), dated July 3, 2022, Merger Sub merged with and into Tyme (the “Merger”), with Tyme surviving the Merger as a wholly owned subsidiary of Syros.

     

     

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, Tyme Technologies, Inc. has duly caused this certification/notice to be signed on its behalf by the undersigned person.

     

        Tyme Technologies, Inc.
    Date:September 30, 2022      
        By:  

    /s/ Jason Haas

        Name:   Jason Haas
        Title:   Treasurer and Secretary
    Get the next $TYME alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TYME

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $TYME
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Syros and Tyme Technologies Announce Stockholder Approval of Merger

    -- Combined Company to Trade on Nasdaq Under Ticker "SYRS" ---- Syros Announces 1-for-10 Reverse Stock Split of Common Stock -- CAMBRIDGE, Mass. and BEDMINSTER, N.J., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, and Tyme Technologies, Inc. (NASDAQ:TYME) today announced the results of the special meetings of the stockholders of Syros and TYME, respectively, each held on September 15, 2022. At TYME's special meeting, TYME's stockholders voted in favor of all proposals, including the proposal to adopt the agreement and plan of merger, dated July 3, 2022 (the "Merger Agreement"), pu

    9/15/22 4:13:00 PM ET
    $SYRS
    $TYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Syros and Tyme Technologies Announce Stockholder Approval of Merger

    -- Combined Company to Trade on Nasdaq Under Ticker "SYRS" -- -- Syros Announces 1-for-10 Reverse Stock Split of Common Stock -- Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, and Tyme Technologies, Inc. (NASDAQ:TYME) today announced the results of the special meetings of the stockholders of Syros and TYME, respectively, each held on September 15, 2022. At TYME's special meeting, TYME's stockholders voted in favor of all proposals, including the proposal to adopt the agreement and plan of merger, dated July 3, 2022 (the "Merger Agreement"), pursuant to which a direct, wholly owned subsidiary of Syros will merge with

    9/15/22 4:01:00 PM ET
    $SYRS
    $TYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TYME Technologies, Inc. Announces Proxy Advisory Firms Glass Lewis and ISS Recommend Stockholders Vote "FOR" Proposed Merger of Syros and Tyme

    BEDMINSTER, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME) ("Tyme" or the "Company"), today announced that independent proxy advisory firms Glass, Lewis & Co. ("Glass Lewis") and Institutional Shareholder Services Inc. ("ISS") have recommended that Tyme stockholders vote "FOR" the previously announced merger of Tyme and Syros Pharmaceuticals, Inc. ("Syros") and "FOR" all other matters to be voted upon at the Company's upcoming Special Meeting of Stockholders (the "Special Meeting") scheduled for September 15, 2022 at 11:00 a.m., Eastern Time. ISS and Glass Lewis are leading independent, third-party proxy advisory firms who, among other services, provide pro

    9/7/22 8:00:00 AM ET
    $TYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TYME
    SEC Filings

    View All

    SEC Form 15-12G filed by Tyme Technologies Inc.

    15-12G - TYME TECHNOLOGIES, INC. (0001537917) (Filer)

    9/30/22 4:05:54 PM ET
    $TYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Tyme Technologies Inc.

    EFFECT - TYME TECHNOLOGIES, INC. (0001537917) (Filer)

    9/22/22 12:15:06 AM ET
    $TYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Tyme Technologies Inc.

    EFFECT - TYME TECHNOLOGIES, INC. (0001537917) (Filer)

    9/22/22 12:15:20 AM ET
    $TYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TYME
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Sokol Gerald H returned 5,865 shares to the company, closing all direct ownership in the company

    4 - TYME TECHNOLOGIES, INC. (0001537917) (Issuer)

    9/16/22 6:01:07 PM ET
    $TYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4: Porfido Frank L. returned 10,000 shares to the company, closing all direct ownership in the company

    4 - TYME TECHNOLOGIES, INC. (0001537917) (Issuer)

    9/16/22 6:00:57 PM ET
    $TYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4: Biehl James returned 105,150 shares to the company, closing all direct ownership in the company

    4 - TYME TECHNOLOGIES, INC. (0001537917) (Issuer)

    9/16/22 6:00:35 PM ET
    $TYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TYME
    Leadership Updates

    Live Leadership Updates

    View All

    TYME Announces Appointment of Dr. Jan M Van Tornout as Acting Chief Medical Officer

    BEDMINSTER, N.J.--(BUSINESS WIRE)--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced the appointment of Jan M Van Tornout, MD, MSc, as acting Chief Medical Officer, effective April 1, 2021. Dr. Van Tornout will provide leadership and direction for all medical and related preclinical programs in development. He will be replacing Dr. Giuseppe Del Priore. “On behalf of the board of directors, we truly appreciate Giuseppe’s many contributions towards advancing our programs and we wish him continued success in his future endeavors,” said Richie Cunningham, TYME’s CEO. Dr. Van Tornout brings

    4/1/21 8:00:00 AM ET
    $TYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TYME
    Financials

    Live finance-specific insights

    View All

    Syros to Raise Approximately $190 Million Through Merger with TYME Technologies and Concurrent Private Placement

    Combined Company Will Operate as Syros Pharmaceuticals and Continue to Advance Syros' Ongoing Clinical Programs Syros Expects to Have Cash Into 2025; At Least a Year Past SELECT-MDS-1 Pivotal Data Now Planning to Initiate Phase 3 Clinical Trial of SY-2101 in APL 2H 2023 Syros to Host Conference Call at 8:30 AM ET Today Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, and TYME Technologies, Inc. (NASDAQ:TYME), today announced that the companies have entered into a definitive merger agreement pursuant to which Syros will acquire TYME, including its pipeline assets and net cash at closing which after accounting for wind-dow

    7/5/22 7:00:00 AM ET
    $SYRS
    $TYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TYME Technologies, Inc. Provides Business Update and Announces Third Fiscal Quarter 2022 Financial and Operating Results

    – Georgetown University and associated Georgetown Medstar Centers continued enrollment in Phase II OASIS trial evaluating the potential benefits of oral SM-88 for patients with metastatic HR+/HER2- breast cancer after treatment with a CDK4/6 inhibitor – On track for mid-2022 full enrollment of HopES trial for SM-88 used in patients with high-risk Ewing's and other sarcoma types – Pursuing options to diversify the clinical pipeline – Well-capitalized position, with $92.0 million in cash and marketable securities as of December 31, 2021 – Company to host live conference call and webcast today, February 11, at 8:30 AM ET TYME Technologies, Inc. (NASDAQ:TYME) (the Company or TYME), an emer

    2/11/22 6:50:00 AM ET
    $TYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TYME Technologies, Inc. to Host Conference Call and Webcast on Friday, February 11, at 8:30 AM ET

    TYME Technologies, Inc. (NASDAQ:TYME) (the "Company" or "TYME"), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced that the Company will report its third quarter 2022 financial results on Friday, February 11, 2022, at 8:30 AM ET. Richie Cunningham, Chief Executive Officer, and Frank Porfido, Chief Financial Officer, will host a conference call and webcast as follows: Date: Friday, February 11, 2022 Time: 8:30 AM ET Toll-free (U.S.) (866) 601-3896 International (636) 812-6499 Conference ID 1286376 The webcast will be accessible on the Events & Presentations page of the Investors s

    1/27/22 4:30:00 PM ET
    $TYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TYME
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Tyme Technologies Inc. (Amendment)

    SC 13G/A - TYME TECHNOLOGIES, INC. (0001537917) (Subject)

    9/16/22 4:34:58 PM ET
    $TYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Tyme Technologies Inc. (Amendment)

    SC 13G/A - TYME TECHNOLOGIES, INC. (0001537917) (Subject)

    2/8/22 7:00:52 AM ET
    $TYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - TYME TECHNOLOGIES, INC. (0001537917) (Subject)

    2/12/21 4:07:03 PM ET
    $TYME
    Biotechnology: Pharmaceutical Preparations
    Health Care